By Deena Beasley SAN DIEGO, June 23 (Reuters) - U.S. biotechnology industry trade group BIO worked with the Food and Drug ...
The US Food and Drug Administration (FDA) has released a call for comments on a new transparency and drug review program contained within the Prescription Drug User Fee Act V (PDUFA V), which is ...
FDA Commissioner Marty Makary announced a new pilot program that will provide bonus payments to drug reviewers who complete their evaluations ahead of schedule. This initiative aims to enhance the ...
The Food and Drug Administration on Thursday announced the first round of experimental drugs that will receive drastically expedited reviews at the agency, part of an effort to prioritize medicines ...
By Puyaan Singh June 29 (Reuters) - The New England Journal of Medicine on Monday retracted an article on a pivotal clinical ...
Zacks Investment Research on MSN
OTLK stock up 35% as FDA accepts resubmitted eye drug BLA for review
Shares of Outlook Therapeutics OTLK rallied 35.3% on Tuesday after the company announced that the FDA accepted the resubmitted Biologics License Application (BLA) for ONS-5010/Lytenava, its ...
With an eye toward reducing review cycles for abbreviated new drug applications (ANDAs) and better informing industry of the roles and responsibilities of US Food and Drug Administration (FDA) review ...
FDA’s rolling review process is intended to facilitate expedited review, enabling FDA to begin evaluating completed sections ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results